IL-2 is a key cytokine involved in immune system homeostasis and T-cell maintenance and was previously approved by the FDA as immunotherapy for metastatic renal cell carcinoma and metastatic melanoma [28]. The gene discussed is IL2; the disease is metastatic melanoma.